CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The approval of ipilimumab for the treatment of melanoma is a major step forward in cancer immunotherapy. The randomized Phase II trials yielded improvement in irPFS in both small-cell lung cancer and non-squamous-cell lung cancer patients treated with two cycles of chemotherapy followed by chemotherapy combined with ipilimumab. Ipilimumab is currently being evaluated for the treatment of squamous-cell lung cancer and small-cell lung cancer.

Original languageEnglish (US)
Title of host publicationTargeted Therapies for Non-Small-Cell Lung Cancer
PublisherFuture Medicine Ltd.
Pages47-54
Number of pages8
ISBN (Electronic)9781780840468
ISBN (Print)9781780841236
DOIs
StatePublished - Oct 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Brahmer, J. R. (2012). CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC. In Targeted Therapies for Non-Small-Cell Lung Cancer (pp. 47-54). Future Medicine Ltd.. https://doi.org/10.2217/EBO.12.28